Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROQURE-1: Concurrent EBRT + Lu-PSMA for Node-positive Prostate Cancer
NCT05162573Phase 1Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Dec 2021
- Primary completion
- Sep 2025
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label trial of lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa) (4 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Maximum Tolerated Dose at 3 months. Started Dec 2021; status: completed.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05162573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05162573.